Equities analysts predict that Veru Inc (NASDAQ:VERU) will post sales of $9.26 million for the current quarter, according to Zacks. Three analysts have made estimates for Veru’s earnings, with the highest sales estimate coming in at $11.19 million and the lowest estimate coming in at $8.20 million. Veru posted sales of $5.20 million in the same quarter last year, which suggests a positive year over year growth rate of 78.1%. The firm is expected to issue its next earnings report on Thursday, December 12th.

On average, analysts expect that Veru will report full year sales of $32.35 million for the current financial year, with estimates ranging from $31.30 million to $34.26 million. For the next year, analysts anticipate that the firm will post sales of $34.96 million, with estimates ranging from $33.90 million to $35.97 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Veru.

Veru (NASDAQ:VERU) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.04) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.04). The business had revenue of $9.73 million for the quarter, compared to analyst estimates of $8.11 million. Veru had a negative return on equity of 50.14% and a negative net margin of 59.68%.

A number of equities research analysts recently commented on the company. ValuEngine lowered Veru from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. HC Wainwright restated a “buy” rating on shares of Veru in a research report on Thursday, October 3rd. Zacks Investment Research lowered Veru from a “hold” rating to a “sell” rating in a research report on Saturday, October 12th. Cantor Fitzgerald began coverage on Veru in a research report on Monday, July 1st. They issued an “overweight” rating and a $6.00 price objective on the stock. Finally, Brookline Capital Management began coverage on Veru in a research report on Monday, July 29th. They issued a “buy” rating and a $12.00 price objective on the stock. Two research analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $5.71.

In other Veru news, CEO Mitchell Shuster Steiner sold 30,000 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $1.93, for a total value of $57,900.00. Also, CFO Michele Greco purchased 20,000 shares of Veru stock in a transaction dated Tuesday, August 20th. The stock was bought at an average price of $1.84 per share, for a total transaction of $36,800.00. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 47,000 shares of company stock worth $89,040 and sold 90,000 shares worth $189,158. 29.50% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of the company. Perceptive Advisors LLC boosted its position in shares of Veru by 1.4% in the 2nd quarter. Perceptive Advisors LLC now owns 1,445,000 shares of the company’s stock worth $3,078,000 after purchasing an additional 20,000 shares during the last quarter. BlackRock Inc. boosted its position in shares of Veru by 65.4% in the 2nd quarter. BlackRock Inc. now owns 228,934 shares of the company’s stock worth $487,000 after purchasing an additional 90,530 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Veru by 183.1% in the 2nd quarter. Renaissance Technologies LLC now owns 262,160 shares of the company’s stock worth $558,000 after purchasing an additional 169,550 shares during the last quarter. Finally, Wedge Capital Management L L P NC bought a new position in shares of Veru in the 2nd quarter worth $394,000. Institutional investors and hedge funds own 8.83% of the company’s stock.

NASDAQ VERU remained flat at $$2.12 during trading hours on Monday. The company had a trading volume of 88,848 shares, compared to its average volume of 51,122. The company has a market cap of $137.88 million, a PE ratio of -5.44 and a beta of 0.41. Veru has a 1-year low of $1.18 and a 1-year high of $2.49. The business’s 50 day simple moving average is $2.02 and its two-hundred day simple moving average is $1.91. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.20 and a current ratio of 1.47.

About Veru

Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

Further Reading: Cost of Debt

Get a free copy of the Zacks research report on Veru (VERU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.